Burnaby
Burnaby
Burnaby, British Columbia, Canada16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT07047118 | |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Multiple Sclerosis, Primary Progressive, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-09-17 | NCT04544449 | |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-09-16 | NCT06463587 | |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) | Charcot-Marie-Tooth disease type 1F, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Active, not recruiting | Phase 3 | 2026-08-18 | NCT05156281 | |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-08-17 | NCT06372145 | |
| A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03523858 | |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-06-22 | NCT05918861 | |
| Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Not stated | 2026-06-18 | NCT05966467 | |
| A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | CNS demyelinating autoimmune disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Phase 4 | 2026-05-29 | NCT05090371 | |
| ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS | CNS demyelinating autoimmune disease, Charcot-Marie-Tooth disease type 1F, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 4 | 2026-05-15 | NCT06733922 | |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-05-14 | NCT06141486 | |
| Postural Sway and Counterpressure Maneuvers for Pediatric Syncope | Consciousness Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Syncope, Syncope, Vasovagal, Unconsciousness, autonomic nervous system disorder, nervous system disorder, orthostatic intolerance, primary dysautonomia | Recruiting | Not applicable | 2026-04-23 | NCT05633693 | |
| The Effect of Water Carbonation on Orthostatic Tolerance | Consciousness Disorders, Hypotension, Orthostatic, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Syncope, Syncope, Vasovagal, Unconsciousness, autonomic nervous system disorder, cardiovascular disorder, hypotensive disorder, nervous system disorder, orthostatic intolerance, primary dysautonomia, vascular disorder | Recruiting | Not applicable | 2026-04-23 | NCT05621460 | |
| Can a Single-session Intervention Decrease Risk for Mental Health Symptoms in Young Adults? A Preliminary Investigation of Feasibility and Acceptability | Feeding and Eating Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, depressive disorder, psychiatric disorder | Not yet recruiting | Not applicable | 2025-09-12 | NCT07149324 | |
| Impact of Blood Phobia on Fainting Susceptibility | Consciousness Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Syncope, Syncope, Vasovagal, Unconsciousness, autonomic nervous system disorder, nervous system disorder, orthostatic intolerance, primary dysautonomia | Recruiting | Not applicable | 2025-05-15 | NCT06336031 | |
| Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults | immune system disorder, inborn error of immunity | Recruiting | Phase 2 | 2025-01-22 | NCT05421325 |